Celesq® Programs

Insights from First Securities Fraud Class Action Against a Company Developing a COVID-19 Vaccine

Expired
Program Number
30104
Program Date
2020-04-21

This program will focus on heightened risk factors for publicly traded companies when providing information to investors and provide insights about such risk factors using the recent securities fraud class action filed against Inovio Pharmaceuticals Inc. and its CEO as an example. The faculty will review the theories of securities fraud commonly relied upon, such as the fraud-on-the market theory, along with measures to avoid or limit these risks.

Available in States

  • California
  • Georgia
  • New Jersey
  • New York
  • Texas Self Study

Program Categories

  • Business Organizations & Contracts
  • Complex Litigation
  • Contracts
  • Corporate and Securities Law
  • Covid-19
  • Federal Courts
  • Health Care Law
  • Litigation & Litigation Skills
  • Pharmaceutical Law
  • Securities and Antitrust Litigation